

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**中國太平洋保險(集團)股份有限公司**

**CHINA PACIFIC INSURANCE (GROUP) CO., LTD.**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 02601)**

### **Overseas Regulatory Announcement**

This overseas regulatory announcement is made pursuant to Rule 13.09 and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The announcement is attached hereof for information purpose only.

By Order of the Board  
**China Pacific Insurance (Group) Co., Ltd.**  
**FU Fan**  
*Chairman*

Hong Kong, 27 March 2025

*As at the date of this announcement, the Executive Directors of the Company are Mr. FU Fan and Mr. ZHAO Yonggang; the Non-executive Directors are Mr. HUANG Dinan, Mr. WANG Tayu, Mr. CHEN Ran, Mr. ZHOU Donghui, Mr. XIE Weiqing, Ms. LU Qiaoling, Mr. CAI Qiang, John and Mr. John Robert DACEY; and the Independent Non-executive Directors are Ms. LIU Xiaodan, Ms. LAM Tyng Yih, Elizabeth, Ms. LO Yuen Man, Elaine, Mr. CHIN Hung I David and Mr. JIANG Xuping.*

# Summary of Solvency Report (Excerpts)

CHINA PACIFIC INSURANCE (GROUP) CO., LTD.

2024

## Company overview and contact information

|                              |   |
|------------------------------|---|
| Company name (Chinese):      | 中国太平洋保险（集团）股份有限公司   |
| Company name (English):      | CHINA PACIFIC INSURANCE (GROUP) CO., LTD.   |
| Legal representative:        | FU Fan  |
| Registered address:          | 1 Zhongshan Road (South), Huangpu District,<br>Shanghai, PRC.   |
| Registered capital:          | RMB9.62 billion   |
| Business license number:     | 000013  |
| First date for registration: | May 13, 1991  |
| Business scope:              | Invest in controlling stakes of insurance companies;<br>supervise and manage the domestic and<br>international reinsurance business of the insurers<br>under its control; supervise and manage the<br>investments by the insurers under its control;<br>participate in international insurance activities as<br>approved. |
| Contact person:              | HUANG Danyan  |
| Office Tel. number:          | 021-33968093  |
| Cell phone:                  | 13764517031   |
| Fax number:                  | 021-58792445  |
| E-mail:                      | <a href="mailto:huangdanyan@cpic.com.cn">huangdanyan@cpic.com.cn</a>  |

---

## **CONTENTS**

|   |    |
|---|----|
| I. BOARD AND MANAGEMENT STATEMENT .....               | 4  |
| II. BASIC INFORMATION .....                           | 5  |
| III. BUSINESS OPERATION OF MAJOR MEMBER COMPANIES ... | 7  |
| IV. SOLVENCY STATEMENTS .....                         | 8  |
| V. MANAGEMENT ANALYSIS AND DISCUSSIONS .....          | 9  |
| VI. RISK MANAGEMENT CAPABILITIES .....                | 11 |
| VII. INTEGRATED RISK RATING .....                     | 17 |

## I. Board and management statement

The report has been approved by the board of directors. The board and the senior management of the Company warrant that the contents of this report are true, accurate and complete and have fully complied with applicable laws and regulations, and that there is no false representation, misleading statements or material omissions; and they severally and jointly accept responsibility for the contents of this report.

### 1. Voting results by directors

| Name of directors       | For | Against | Abstain |
|-------------------------|-----|---------|---------|
| WANG Tayu               | ✓   |         |         |
| LIU Xiaodan             | ✓   |         |         |
| CHEN Ran                | ✓   |         |         |
| LAM Tyng Yih, Elizabeth | ✓   |         |         |
| LO Yuen Man, Elaine     | ✓   |         |         |
| CHIN Hung I David       | ✓   |         |         |
| ZHOU Donghui            | ✓   |         |         |
| ZHAO Yonggang           | ✓   |         |         |
| JIANG Xuping            | ✓   |         |         |
| HUANG Dinan             | ✓   |         |         |
| FU Fan                  | ✓   |         |         |
| XIE Weiqing             | ✓   |         |         |
| LU Qiaoling             | ✓   |         |         |
| CAI Qiang, John         | ✓   |         |         |
| John Robert DACEY       | ✓   |         |         |
| Total                   | 15  |         |         |

Note: Mark “ ✓ ” in corresponding blanks according to opinions of directors.

2. Are there any directors who cannot guarantee or harbor any doubt about the truthfulness, accuracy, completeness or compliance of the contents of this report? (yes  no )

## II. Basic Information

### (I) Shareholding structure, shareholders and change

#### 1. Shareholding structure (unit: share)

|   | As at the beginning of the reporting period |                | Increase or decrease (+ or -) in shareholding during the reporting period |              |                        |        |           | As at the end of the reporting period |                |
|---|---|----------------|---|--------------|------------------------|--------|-----------|---------------------------------------|----------------|
|   | Amount                                      | Percentage (%) | New shares issued   | Bonus shares | Transfer from reserves | Others | Sub-total | Amount                                | Percentage (%) |
| 1. Ordinary shares denominated in RMB       | 6,845,041,455                               | 71.15          | -   | -            | -                      | -      | -         | 6,845,041,455                         | 71.15          |
| 2. Domestically listed foreign shares       | -   | -              | -   | -            | -                      | -      | -         | -                                     | -              |
| 3. Overseas listed foreign shares (H share) | 2,775,300,000                               | 28.85          | -   | -            | -                      | -      | -         | 2,775,300,000                         | 28.85          |
| 4. Others                                   | -   | -              | -   | -            | -                      | -      | -         | -                                     | -              |
| Total                                       | 9,620,341,455                               | 100.00         | -   | -            | -                      | -      | -         | 9,620,341,455                         | 100.00         |

#### 2. Top 10 shareholders (unit: share)

| Name of shareholders       | Percentage of shareholding | Total number of shares held | Increase or decrease (+ or -) of shareholding during the reporting period | Number of shares subject to pledge or lock-up | Type of shares |
|----------------------------|----------------------------|-----------------------------|---|---|----------------|
| HKSCC Nominees Limited     | 28.82%                     | 2,772,616,357               | +33,250   | -   | H Share        |
| Shenergy (Group) Co., Ltd. | 14.05%                     | 1,352,129,014               | -   | -   | A Share        |

|   |  |               |             |   |         |
|---|--|---------------|-------------|---|---------|
| Hwabao Investment Co., Ltd.   | 13.35%   | 1,284,277,846 | -           | - | A Share |
| Shanghai State-Owned Assets Operation Co., Ltd.                                       | 6.34%  | 609,929,956   | -           | - | A Share |
| Shanghai Haiyan Investment Management Company Limited                                 | 4.87%  | 468,828,104   | -           | - | A Share |
| HKSCC   | 2.83%  | 272,020,360   | +35,494,368 | - | A Share |
| China Securities Finance Co., Ltd.  | 2.82%  | 271,089,843   | -           | - | A Share |
| Shanghai International Group  | 1.66%  | 160,000,000   | -           | - | A Share |
| Yunnan Hehe (Group) Company Limited   | 0.95%  | 91,868,387    | -           | - | A Share |
| Shanghai Jiushi Company Limited   | 0.95%  | 90,949,460    | +1,211,700  | - | A Share |
| Description of related relations or concerted actions among the aforesaid shareholder | <p>HKSCC Nominees Limited and HKSCC are connected, as the former is a wholly-owned subsidiary of the latter. Shanghai State-Owned Assets Operation Co., Ltd. is a wholly-owned subsidiary of Shanghai International Group, and they act in concert. Based on inquiries of the Company and confirmation of relevant shareholders, other than that, the Company is not aware of any other connected relations or concerted actions among the above-mentioned shareholders.</p> |               |             |   |         |

Notes:

1. As at the end of the reporting period, the Company did not issue any preferred shares.
2. The shareholding of the top 10 shareholders is based on the lists of registered shareholders provided by China Securities Depository and Clearing Corporation Limited Shanghai Branch (A share) and Computershare Hong Kong Investor Services Limited (H share) respectively. The nature of A shareholders is the same as the nature of their accounts registered with China Securities Depository and Clearing Corporation Limited Shanghai Branch.
3. The shares held by HKSCC Nominees Limited are held on behalf of its clients. As SEHK does not require such shareholders to disclose to HKSCC Nominees Limited whether the shares held by them are subject to pledge or lock-up period, HKSCC Nominees Limited is unable to calculate, or make actual such data. Pursuant to Part XV of the SFO, a Substantial Shareholder is required to give notice to SEHK and the Company on the occurrence of certain events including a change in the nature of its interest in shares such as the pledging of its shares. As at the end of the reporting period, the Company is not aware of any such notices from Substantial Shareholders under Part XV of the SFO.
4. HKSCC is the nominal holder of shares traded through Shanghai-Hong Kong Connect Programme.

### **III. Business Operation of Major Member Companies**

#### **(I) CPIC Life**

CPIC Life maintained solid profitability. In 2024, the subsidiary recorded written premiums of 261.080bn yuan, a year-on-year growth of 3.3%; net profits of 35.821bn yuan, a year-on-year growth of 83.4%.

As of the end of 2024, its comprehensive solvency margin ratio was 210%, staying largely flat versus that as at the end of 2023, mainly due to impact of interest rate movements, capital market fluctuation, business development, changes to asset allocation and issuance of bonds. Of this,

- (1) Actual capital amounted to 345.510bn yuan, up by 10.7%, or 33.305bn yuan from the end of 2023;
- (2) Minimum capital 164.313bn yuan, up by 10.5%, or 15.590bn yuan from the end of 2023.

#### **(II) CPIC P/C**

In the reporting period, the subsidiary pursued progress while ensuring stable fundamentals and continued to boost high-quality development. It reported 201.243bn yuan in primary premium income, a year-on-year growth of 6.8%, and net profits of 7.376bn yuan, a growth of 12.2% from 2023.

As of the end of 2024, its comprehensive solvency margin ratio stood at 222%, up by 8pt from the end of 2023, mainly due to impact of interest rate movements, capital market fluctuation, business development and changes to asset allocation. Of this,

- (1) Actual capital amounted to 70.698bn yuan, up by 8.923bn yuan from the end of 2023, or a growth of 14.4%;
- (2) Minimum capital 31.852bn yuan, up by 2.954bn yuan, or 10.2% from the end of 2023.

#### **(III) CPIC Health**

The company maintained rapid business growth. During the reporting period, it realised 2.735bn yuan in insurance revenue and health management fee income, a growth of 31.6%; net profits reached 91mn yuan, a growth of 193.5% year on year.

As of the end of 2024, its comprehensive solvency margin ratio stood at 235%, down by 23pt from the end of 2023, mainly due to interest rate movements, capital market fluctuation,



business development and changes to asset allocation. Of this,

(1) Actual capital amounted to 4.040bn yuan, up by 15.9%, or 552mn yuan from the end of 2023;

(2) Minimum capital 1.716bn yuan, up by 27%, or 364mn yuan from the end of 2023.

#### (IV) CPIC AMC

As of the end of 2024, it posted 294.187bn yuan in third-party AuM, up by 30.7% from the end of 2023.

#### (V) Changjiang Pension

As at 31 December 2024, Changjiang Pension recorded 481.309bn yuan in third-party assets under trustee management, up by 17.1% from the end of 2023; 406.401bn yuan in third-party assets under investment management, up by 15.4% from the end of 2023.

#### (VI) Other member companies

As of the end of 2024, total assets of CPIC Property reached 200mn yuan, with net assets of 161mn yuan; total assets of CPIC Technology reached 1.994bn yuan, with net assets of 730mn yuan.

## IV. Solvency Statements

### Solvency Statements of Insurance Holding Groups

Name: **China Pacific Insurance (Group) Co. Ltd.**

(31 December, 2024)

unit: 10 thousand RMB yuan

| Items                     | No. of lines                | As at the end of the reporting period<br>1 | As at the beginning of the reporting period<br>2 |
|---------------------------|-----------------------------|--|--|
| Actual capital            | (1) = (2) + (3) + (4) + (5) | 50,374,512                                 | 45,693,824                                       |
| Tier 1 core capital       | (2)                         | 33,786,832                                 | 29,176,067                                       |
| Tier 2 core capital       | (3)                         | 2,020,919                                  | 1,214,761  |
| Tier 1 supplement capital | (4)                         | 14,556,259                                 | 15,298,572                                       |
| Tier 2 supplement capital | (5)                         | 10,502                                     | 4,424  |

|  |  |            |            |
|--|--|------------|------------|
| Minimum capital  | $(6) = (7) + (21) + (22)$                            | 19,707,913 | 17,801,725 |
| Minimum capital for quantitative risks                       | $(7) = (8) + (9) + (10) + (11) + (12) + (13) - (20)$ | 19,938,945 | 18,012,787 |
| Minimum capital for parent company                           | (8)  |            |            |
| Minimum capital for insurance member companies               | (9)  | 19,938,945 | 18,012,787 |
| Minimum capital for banking member companies                 | (10)   | -          | -          |
| Minimum capital for securities member companies              | (11)   | -          | -          |
| Minimum capital for trust member companies                   | (12)   | -          | -          |
| Minimum capital for quantifiable group-specific risks        | $(13) = (14) + (15)$                                 | -          | -          |
| Minimum capital for risk contagion                           | (14)   | -          | -          |
| Minimum capital for concentration risk                       | $(15) = (16) + (17) + (18) - (19)$                   | -          | -          |
| Minimum capital for concentration risk - counter parties     | (16)   | -          | -          |
| Minimum capital for concentration risk - industry            | (17)   | -          | -          |
| Minimum capital for concentration risk - customers           | (18)   | -          | -          |
| Risk diversification effect                                  | (19)   | -          | -          |
| Decrease in required capital for risk diversification effect | (20)   | -          | -          |
| Minimum capital for control risk                             | (21)   | (231,032)  | (211,061)  |
| Supplement capital   | (22)   |            | -          |
| Core solvency margin   | $(23) = (2) + (3) - (6) \times 50\%$                 | 25,953,795 | 21,489,965 |
| Core solvency margin ratio                                   | $(24) = [(2) + (3)] / (6) \times 100\%$              | 182%       | 171%       |
| Comprehensive solvency margin                                | $(25) = (1) - (6)$                                   | 30,666,599 | 27,892,098 |
| Comprehensive solvency margin ratio                          | $(26) = (1) / (6) \times 100\%$                      | 256%       | 257%       |

Note: Decrease in required capital for risk diversification effect and supplement capital at the group level are yet to be defined by the regulator.

## V. Management Analysis and Discussions

### (I) Analysis of solvency margin ratio movements during the reporting period

As of the end of 2024, Group comprehensive solvency margin ratio stood at 256%, down by

1pt from the end of 2023; core solvency margin ratio was 182%, up by 11pt from the end of 2023, mainly due to interest rate movements, business development, changes to asset allocation and bond issuance of its subsidiaries. Of this,

1) Actual capital amounted to 503.7bn yuan, up by 46.8bn yuan from the end of 2023; core capital 358.1bn yuan, up by 54.2bn yuan from the end of 2023.

2) Minimum capital 197.1bn yuan, up by 19.1bn yuan from the end of 2023.

In short, Group solvency margin ratios stayed solid, all above regulatory minimum levels.

## **(II) Analysis of changes to IRR and Group risk status during the reporting period**

The regulator is yet to carry out Integrated Risk Rating for insurance groups.

In 2024, the Group maintained sound and stable operation overall with effective implementation of its risk appetite. All the risk indicators remained stable, with the overall risk under control. There was no occurrence of risk events with significant impact on its business operation or solvency in the reporting period.

In 2025, the international landscape remains complex and challenging. China's economic recovery is on track, but still faces the risk of disruption of the external environment and the downward pressure during transition of growth drivers. The new "10-Point Guidelines" of the insurance sector called for tightening of regulation to forestall major risks and considered it as the precondition of high-quality development. A host of measures have been taken to push for return to the basics of the industry and high-quality development. However, there is mounting pressure on matching assets and liabilities amid the decline of interest rates; extreme weather events and natural disasters will drive up the combined ratio of P/C insurance business; pilot programmes of insurance fund investment and use of new technologies require more effective risk management.

In the face of such risks, we will stay prudent in our risk appetite to pursue high-quality development based on effective risk control. We'll carefully handle risks and uncertainties in our business operation and leverage insurance as a "cushion of economic shocks" and a "social stabiliser". To this end, first, we'll adhere to value growth, enhance the role of risk appetite as a key constraint for business development and maintain high ratings at regulatory evaluation; second, focus on key risk areas, adopt a "look-through" approach, improve coordination in control of major risks to solidify the "lines of defence"; third, enhance digitalisation and use of AI technology, roll out on-line systems for risk identification, risk assessment, risk monitoring and risk early warning, so as to improve the effectiveness of forward-looking risk management in an all-around way.

## **VI. Risk Management Capabilities**

### **(I) Group solvency risk governance**

The Company has established a broad-based risk management framework in which all parties involved play their due roles: the Board of Directors bears the ultimate responsibility, management provides direct leadership, risk management departments focus on coordination, and the 3 lines of defense closely work together. The boards of directors of the Group and its subsidiaries are the supreme authority in risk management of the organisation, and bear the ultimate responsibility for their respective risk management systems and status of operation. The board Risk Management Committee performs duty in risk management as is vested by the board. In 2024, the committee convened 5 meetings to review relevant risk management matters and reports.

The Company's Management Committee is mandated to organise and execute the Company's risk management activities. The Company set up the position of Chief Risk Officer, who reports to the board Risk Management Committee on risk exposure and management measures of the Company on a quarterly basis. The Management Committee has under it a Working Group of Risk Management and Internal Audit.

The Group has set up the Risk Management Department responsible for coordinating daily work in risk management. All insurance/asset management member companies of the Group have set up Risk Management Departments, which coordinate and implement various decisions made by the management in the field of risk management, and organise, direct and supervise other departments in execution of daily risk management tasks determined by management. All the other functional departments of the Group and subsidiaries and their branches have appointed responsible persons for risk management and set up corresponding positions, who are responsible for the risk management work within their scope of responsibility and communication with the risk management department.

The Group Internal Audit Centre audits, on an annual basis, the status and results of operation of the Group's solvency-aligned risk management system, as well as the status of implementation of risk management policies, and reports to the board.

### **(II) Risk management strategies and implementation**

#### **1. Risk management strategies**

The overall risk management strategy of the Company is: in view of its development

strategies, organisational structure and business characteristics, support and promote fulfillment of business objectives and strategic planning of the Company via a sound risk management system, stringent risk management processes, and scientific risk management mechanisms and tools under the guidance of risk management objectives.

Risk management is a core element of the Company's operation and management. The Company takes a centralised approach to risk management and sets up an overarching risk management framework with centralised design of risk management organisational structure, unified risk management objectives, unified risk management policies and core risk measurement tools, and unified design and development of risk management information systems to guide and supervise the Group's risk management work. While maintaining their independent risk governance and setting up necessary firewalls, each subsidiary is responsible for managing various risks within their business segment in accordance with the basic goals and policies, systems and processes, methods and tools of the Group's risk management.

## **2. Risk appetite systems and objectives**

Based on its rules on risk appetite system, the Company formulates the Group Risk Appetite System, which is reviewed and updated on an annual basis when necessary.

The Company adopts a "prudent" risk appetite, and cautiously manages various risks in its business operation. The Company and its insurance subsidiaries maintain a sufficient level of solvency, and pursue stable profitability and sustained value growth while ensuring appropriate liquidity, maintain a sound risk management status and market image. It continuously upgrades the risk control system that is compatible with its status as a listed company on SSE, SEHK, and LSE, integrates ESG requirements into the ERM system, with leadership in promoting healthy and stable development of the industry.

The Company's risk tolerance includes five core dimensions: maintaining adequate capital, pursuing stable profitability, achieving sustained value growth, ensuring appropriate liquidity, and maintaining a sound risk management status and a good market image. The Company sets overall risk limits and cascades them to its subsidiaries. Based on their respective business characteristics and needs, each subsidiary further breaks down the limits for various risks and applies them to daily business decisions, risk monitoring and early warning to achieve an optimal balance between risk management and business development.

## **3. Risk management tools**

The Company uses a wide range of risk management tools, including risk management information system, comprehensive budgeting, asset liability management, capital planning and stress testing, etc., to manage the risks within the business scope of the Group and its major member companies. The Group and all its member companies have clearly defined their respective risk management plans and processes, and regularly monitor and supervise their implementation to ensure effective application of the tools.

To be specific, first, the Company set up a risk management information system to monitor key risk indicators and gradually achieve the transmission of financial statements and data between business departments and branches. Second, it adopted comprehensive budgeting management, put in place relevant rules and policies, and formulated scientific business plans to help it achieve the medium- and long-term development objectives based on its overarching strategic plans, risk appetite, goals of sustainable value growth, and by means of budget preparation, implementation, analysis, adjustment and evaluation. The member companies effectively promote the implementation of comprehensive budgeting under the guidance of the Group. Third, in ALM, the Company formulated asset liability management rules, and continuously develops, implements, monitors and refines its asset liability management framework and strategies under its risk appetite and other constraints. Fourth, in terms of capital planning, the Company established a sound capital management system. In compliance with regulatory requirements, it assesses various risks and their capital requirements, putting in place a diversified capital replenishment mechanism to ensure that it is adequately capitalised to withstand risks and meet business development needs. The capital planning of each member company aligns with that of the Group. Fifth, in terms of stress testing, the Company adopted a coordinated stress testing model that is both unified and differentiated, whereby the Group Management Committee takes direct leadership, with clear division of responsibilities and close cooperation between relevant departments and member companies, ensuring highly-efficient implementation. The Group sets out unified objectives, methods and standards of stress testing, carries out stress testing for headquarters and the entire Group; while member companies are responsible for their respective stress testing work, as well as providing the required data and professional opinions as per Group stress testing requirements.

### **(III) Identification and assessment of Group-specific risks**

## **1.Risk contagion**

Risk contagion means that the risk of a member company may spread to other member companies of the same group through internal related party transactions or other means, thus causing unexpected losses to the group or other member companies. CPIC strictly controls related party transactions (RPTs), enhances risk quarantine mechanisms to minimise the risk of contagion. During the reporting period, relevant measures and their implementation status are as follows:

In term of related party transaction management, as per relevant regulatory requirements, the Company has in place, and continuously improves long-term mechanisms for RPT management, strengthens internal control and risk management to curb intra-Group risk contagion resulting from RPTs, pushes forward the building of RPT management systems, enhances accuracy and data-processing capacity of the RPT management process, in a bid to improve full-process, system-driven management. The Company formulated Regulations on Related Party Transactions and its Implementation Rules, established the board Risk Management and Related Party Transactions Control Committee, set up the cross-departmental Office of Related Party Transactions at management level, with clear definition of relevant management roles and responsibilities. During the reporting period, the Company continued to optimise risk limit indicators on major RPTs, further standardised RPT data filing and enhanced the overall management of related party transactions.

As for risk quarantine, in strict conformity with regulatory requirements, the Company put in place a risk quarantine system, formulated relevant rules and policies, specified requirements for “risk firewalls” in areas such as corporate management, financial management, fund management, business operation, information management, personnel management, as well as brand & publicity, information disclosure, related party transactions and guarantee management; identified risk contagion routes, established and implemented prudent risk quarantine management mechanisms and measures. During the reporting period, the Company revised and issued Regulations on Risk Quarantine Management, which helped to update relevant business rules and policies; assessed, on a regular basis, status of risk quarantine management, completed annual assessment report on IT outsourcing as per regulatory requirements; proceeded with self-review of risk quarantine in finance, guarantee and business operation, in a bid to further strengthen the effectiveness of risk quarantine

management.

## **2. Risk of opaque organizational structure**

It refers to the risk that an insurance group's shareholding structure, management structure, operational process, business types, etc. are excessively complex and opaque, which may cause losses to the Group. In strict compliance with regulatory requirements, the Company revised and issued Regulations on Management of Opaque Organisational Structure in 2024, which set out new mechanisms and requirements in managing the risk of opaque organisational structure of the entire Group. The status of the risk in 2024 is as follows:

As a publicly listed insurance holding group, CPIC maintains clear, transparent shareholding and management structures. There is no breach of limits on levels of shareholding or management hierarchy, nor is there any cross-shareholding or illegal subscription of capital instruments between its insurance member companies and other associated companies, or between insurance member companies.

In terms of organisational function, the Group and each of its subsidiaries have established compatible organisational structures based on their respective strategic planning and business development needs, with a management matrix both vertically along corporate functions and horizontally across business units. There is a clear organisational boundary between the Group and its subsidiaries, which helped to avoid either overlapping of or gaps in functions, or over-centralisation of authority and powers, and helped to build work mechanisms with clear definition of roles and responsibilities, good coordination and checks and balances.

## **3. Concentration risk**

Concentration risk refers to the risk of unexpected losses for an insurance group as a result of aggregation of individual risks or risk portfolios of member companies at the group level.

In terms of organisational support, the board of directors of the Company bears the ultimate responsibility for risk management including that of the concentration risk; the management is responsible for execution of risk management work including in concentration risk; the Company put in place centralised concentration risk management mechanisms led by the Risk Management Department, with collaboration from other functional departments. Departments under the framework implement concentration risk management at the Group



level and provide guidance to major member companies on implementation. Major member companies coordinate with the Group in concentration risk management, and develop their own concentration risk management mechanisms for day-to-day implementation.

As for risk management strategy and implementation, In accordance with relevant regulatory requirements, CPIC formulates policies on concentration risk management, regularly identifies, evaluates, monitors and reports on different types of concentration risk along dimensions of transaction counter-parties, underlying industries of investment assets, customers and business, so as to prevent or mitigate material adverse effects of concentration risk on the solvency or liquidity of the Group. In 2024, the Company revised and issued Regulations on Concentration Risks Management, which refined rules and polices of concentration risk management along all dimensions. The Company formulates and annually updates its risk appetite system, which includes upper limits on concentration risk, to be submitted to the board for approval. It conducts evaluation of the status of concentration risk management once every half year, to be reported to the board Risk Management Committee. Based on realities of its business operation and its risk profiles, the Company follows the status of concentration risk relating to investment counter-parties and the credit risk and financial situation of its major counter-parties.

In terms of risk status, during the reporting period, the overall concentration risk status was in the comfort zone. The credit-ratings of the Company's major investment counter-parties remained stable. There was no breach of limits on any dimension, nor occurrence of concentration risk incidents which may pose a material threat to the solvency or liquidity of the Company.

#### **4. Non-insurance risk**

The Company is positioned as “a pure insurance player”, and therefore its non-insurance business and investments focus on areas of health care, elderly care and technology, which aims to promote synergy across industries, boost the supply of insurance products and related services, foster competitive edge in niche markets and ultimately improve its overall competitiveness. The Company strictly complies with relevant regulatory rules and regulations, prudently manages investment activities in non-insurance fields, and constantly monitors and prevents adverse effects of operating activities of non-insurance member companies on the solvency of the Group and its insurance member companies.

In terms of investment by non-insurance member companies, CPIC has established an equity investment management system for non-insurance areas based on equity shareholding and

corporate governance system. It has set up an investment decision-making committee under senior management to organise and coordinate major equity investments of its member companies, which helped to ensure that such investments are in compliance with both regulatory requirements and internal policies of the Group, and are aligned with the risk appetite and risk limits of the Company in non-insurance areas.

In management of its non-insurance business, CPIC strictly complies with relevant regulations, and regularly evaluates the risk exposure of non-insurance investments and their impact on solvency, with findings reported to the board of directors. It also monitors the alignment of non-insurance business and the Group's overall strategic direction, with timely assessment and adjustment, if necessary, of the development strategies of its non-insurance business. The Company has also set up asset and liquidity quarantine mechanisms between its insurance and non-insurance member companies to ensure that investments in non-insurance member companies will not harm the interests of policyholders.

In 2024, the Company reshaped its non-insurance management system, issued Regulations on Non-Insurance Businesses, Regulations on Management of Non-Insurance Subsidiaries and Policies on Non-Insurance Risk Management, striving to strengthen oversight of non-insurance business of the Group in an all-around way through enhanced systems and mechanisms, policies and processes, responsibility and accountability, and supporting tools.

#### **(IV). Results of SARMRA assessment**

In 2022, the regulator conducted an on-site SARMRA assessment of the Company, and the result was 81.77 points. It consisted of 12.28 points for solvency risk governance, 12.76 for risk management strategies and implementation, 9.88 for risk contagion management, 9.6 for risk management of opaque organisational structure, 10.06 for concentration risk management, 9.27 for non-insurance risk management, 8.35 for other risk management, and 9.57 for capital management.

### **VII. Integrated Risk Rating**

#### **(I) IRR results of the previous 2 quarters**

Not applicable. The regulator is yet to carry out Integrated Risk Rating for insurance groups.

#### **(II) Remedial actions taken or to be taken**

Not applicable.